BRPI0507886A - método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o - Google Patents

método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o

Info

Publication number
BRPI0507886A
BRPI0507886A BRPI0507886-5A BRPI0507886A BRPI0507886A BR PI0507886 A BRPI0507886 A BR PI0507886A BR PI0507886 A BRPI0507886 A BR PI0507886A BR PI0507886 A BRPI0507886 A BR PI0507886A
Authority
BR
Brazil
Prior art keywords
solution
composition
purification method
therapeutic use
use containing
Prior art date
Application number
BRPI0507886-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Boulange
Sami Chtourou
Stephane Boyer
Roland Schmitthaeusler
Bruno Padrazzi
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34834103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507886(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BRPI0507886A publication Critical patent/BRPI0507886A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
BRPI0507886-5A 2004-02-27 2005-02-23 método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o BRPI0507886A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0402001A FR2866890B1 (fr) 2004-02-27 2004-02-27 Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
PCT/FR2005/000416 WO2005090402A1 (fr) 2004-02-27 2005-02-23 Procede de purificaton d’albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Publications (1)

Publication Number Publication Date
BRPI0507886A true BRPI0507886A (pt) 2007-08-07

Family

ID=34834103

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507886-5A BRPI0507886A (pt) 2004-02-27 2005-02-23 método de purificação de albumina compreendendo uma etapa de nanofiltração, solução e composição para uso terapêutico contendo-o

Country Status (16)

Country Link
US (3) US20070161122A1 (enExample)
EP (1) EP1718673B1 (enExample)
JP (2) JP4979571B2 (enExample)
AT (1) ATE373014T1 (enExample)
AU (1) AU2005223418B2 (enExample)
BR (1) BRPI0507886A (enExample)
CA (1) CA2557174C (enExample)
CY (1) CY1107082T1 (enExample)
DE (1) DE602005002461T2 (enExample)
DK (1) DK1718673T3 (enExample)
ES (1) ES2294696T3 (enExample)
FR (1) FR2866890B1 (enExample)
IL (1) IL177286A (enExample)
PL (1) PL1718673T3 (enExample)
PT (1) PT1718673E (enExample)
WO (1) WO2005090402A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
FR2887883B1 (fr) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
FR2894831B1 (fr) 2005-12-16 2008-02-15 Lab Francais Du Fractionnement Colle biologique exempte de thrombine et son utilisation comme medicament.
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
CN103429272A (zh) 2010-12-30 2013-12-04 法国化学与生物科技实验室 作为病原体灭活剂的二元醇
FR3004451B1 (fr) * 2013-04-11 2015-12-11 Lab Francais Du Fractionnement Procede de preparation d'une solution de proteine c viralement securisee par une double etape de nanofiltration
EP3119412A1 (en) * 2014-03-21 2017-01-25 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
FR3040882A1 (fr) * 2015-09-10 2017-03-17 Lab Francais Du Fractionnement Composition liquide d'albumine humaine a usage therapeutique
AU2021213787B2 (en) * 2020-01-30 2024-02-29 Fresenius Medical Care Holdings, Inc. Techniques for modelling and optimizing dialysis toxin displacer compounds
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
EP4267210A1 (en) 2020-12-28 2023-11-01 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019919D0 (en) 1990-09-12 1990-10-24 Delta Biotechnology Ltd Purification of proteins
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
US5440018A (en) 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
JPH06279296A (ja) * 1993-03-25 1994-10-04 Asahi Chem Ind Co Ltd 血漿分画製剤中から蛋白質会合物の除去方法
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
KR100827750B1 (ko) * 2000-10-24 2008-05-07 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 인체 혈청알부민 다량체의 단량체화 방법
US6806355B2 (en) * 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
DE10211632A1 (de) * 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
AU2004228847B2 (en) * 2003-04-09 2010-06-17 Km Biologics Co., Ltd. Process for producing albumin preparation
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant

Also Published As

Publication number Publication date
ATE373014T1 (de) 2007-09-15
JP2007535495A (ja) 2007-12-06
DK1718673T3 (da) 2008-01-14
PL1718673T3 (pl) 2008-03-31
DE602005002461T2 (de) 2008-06-12
US9611311B2 (en) 2017-04-04
IL177286A0 (en) 2006-12-10
ES2294696T3 (es) 2008-04-01
EP1718673B1 (fr) 2007-09-12
JP4979571B2 (ja) 2012-07-18
US20150152162A1 (en) 2015-06-04
US20170166626A1 (en) 2017-06-15
AU2005223418A1 (en) 2005-09-29
CA2557174C (fr) 2013-04-30
US10562957B2 (en) 2020-02-18
WO2005090402A1 (fr) 2005-09-29
CY1107082T1 (el) 2012-10-24
FR2866890B1 (fr) 2008-04-04
AU2005223418B2 (en) 2008-12-18
JP2012102115A (ja) 2012-05-31
US20070161122A1 (en) 2007-07-12
EP1718673A1 (fr) 2006-11-08
PT1718673E (pt) 2007-12-13
CA2557174A1 (fr) 2005-09-29
IL177286A (en) 2012-08-30
DE602005002461D1 (de) 2007-10-25
FR2866890A1 (fr) 2005-09-02

Similar Documents

Publication Publication Date Title
CY1107082T1 (el) Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια
ATE462427T1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
DE60230274D1 (de) Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämmen mit verstärkter expression des pts-g
SE0301009D0 (sv) Novel compounds
EP1432310A4 (en) METHOD FOR TREATING CHRONIC CARDIAC INSUFFICIENCY AND / OR HIGH-CHOLESTEROL ACID RATES WITH 3,5-DITODYTHYROPROPIONIC ACID AND PROCESS FOR PREPARING THE SAME
EA200401365A1 (ru) Способы лечения илеуса
EP2628746A3 (en) A process for concentration of a polypeptide
ATE489105T1 (de) Faktor ixa zur behandlung von blutungsstörungen
ATE256695T1 (de) Verfahren zur herstellung von pharmazeutisch annehmbaren salzen des (ss,rs)-s-adenosyl-l- menthionin
DE60322727D1 (de) Rückgefaltetes Membranprotein in monodisperser Form
ATE465998T1 (de) Verfahren zur herstellung und reinigung von 1,7'- dimethyl-2'-propyl-2,5'-bi-1h-benzimidazol
DE602005014280D1 (de) Verfahren zur herstellung von ä1,4,5ü-oxadiazepinderivaten
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
ATE424892T1 (de) Verfahren zur herstellung von derivaten des 4a,5, 9,10,11,12-hexahydrobenzofuro ä3a,3,2üä 2 ü- benzazepins
FI973469A0 (fi) Menetelmä tekijän IX valmistamiseksi biologisista lähteistä
BRPI0416637A (pt) método para produção de uma solução aquosa de etanolamina de cobre e de uma solução de monoetanolamina de cobre
EA200800785A1 (ru) 4-арил-1,4-дигидро-3(2н)-изохинолиноны и 4-арил-1,2,3,4-тетрагидроизохинолины в качестве ингибиторов igf-1r и в качестве фармакологического средства в тест-системах, фармацевтическая композиция и изделие на их основе и способ лечения заболеваний, опосредованных igf-1 рецептором
ATE341558T1 (de) Verfahren zur herstellung von topiramate
RU2003118497A (ru) Способ лечения заболеваний слизистых оболочек
FR2860234B1 (fr) Nouveaux derives 666 du thioxylose
DE602006013688D1 (de) Neues verfahren zur herstellung von thoc
ATE457994T1 (de) Verfahren zur aufreinigung von vancomycin
ATE451367T1 (de) Verfahren zur herstellung von ziprasidon
DE50307320D1 (de) Verfahren zur herstellung von 1,2-dichlorethan mittels direktchlorierung
DE60327567D1 (de) Verfahren zur herstellung von 3,3',4,4'-tetraaminobiphenyl

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time